Breast cancer treatment has long emphasized outcomes such as remission and survival rates, often at the cost of patient well-being. Conventional therapies can inflict severe side effects that compromise quality of life, sometimes with limited additional clinical benefits. Current advancements in precision oncology present a pivotal opportunity—not only to identify more patients for treatment but to focus on those who would benefit from less intensive therapies. This shift aims to reduce overtreatment and its negative consequences on patients' physical and psychological health.
The cascade of treatment options available for breast cancer is both a success and a complication. Although therapies like chemotherapy, radiotherapy, and endocrine treatments have led to improved mortality rates—approximately 2% to 2.5% reductions annually in high-income countries—they can have debilitating side effects. Patients frequently report chronic pain, functional limitations, and changes in body image following surgeries. Chemotherapy and some biologics may lead to infertility, cardiotoxicity, cognitive impairments, and even secondary cancers. Long-term endocrine therapies like tamoxifen, prescribed for periods exceeding five years, are known to cause musculoskeletal pain, depressive symptoms, and increased risks of endometrial cancer and blood clots. The imperative thus arises to better evaluate treatment approaches through de-escalation—a strategy that minimizes treatment intensity without sacrificing patient outcomes.
Key evidence supporting de-escalation lies in genomic risk stratification. Clinical trials such as TAILORx, RxPONDER, and MINDACT have revealed that patients classified with low or intermediate genomic risks often do not derive significant benefits from chemotherapy, even when their clinical recurrence risk is high. This paradigm shift empowers clinicians to spare a subset of patients from unnecessary toxicities while still achieving adequate outcomes.
Additionally, genomic tools like Oncotype DX and MammaPrint are pivotal in this relatively new approach, enabling clinicians to tailor treatments based on individual risk profiles. Emerging technologies such as circulating tumor DNA (ctDNA) hold further promise for monitoring disease progression and enabling timely interventions, although further evidence is needed to gauge their true clinical benefits.
The application of artificial intelligence (AI) in breast cancer management is rapidly evolving. Various AI systems have been integrated into mammographic screening protocols, improving efficiency and detection accuracy. For example, the Transpara system, implemented in the MASAI trial, demonstrated equivalent cancer detection rates compared to traditional methods while significantly reducing radiologist workloads. AI also plays a role in assessing risks and guiding treatment decisions based on genomic data. However, most studies to date focus on diagnostic accuracy rather than actual patient outcomes, underscoring the need for more comprehensive evaluations.
The ramifications of shifting toward de-escalation in breast cancer treatment extend globally, particularly in low- and middle-income countries (LMICs), where breast cancer represents a leading cause of cancer-related mortality among women. In these regions, oncology resources are often sparse, and unnecessary treatments can lead to financial burdens and resource misallocation. By focusing on personalized therapy regimens, healthcare providers can reduce treatment that offers marginal benefits, thus reallocating limited resources to more immediate care needs.
However, challenges persist, including inadequate access to screening and delayed diagnoses that complicate management efforts in these settings. While AI tools may alleviate some constraints related to infrastructure, they must complement ongoing efforts to strengthen health systems.
As the landscape of breast cancer care evolves, there lies an urgent need for research priorities to pivot toward randomized non-inferiority trials evaluating treatment reduction and omission. Future studies should strive to establish if genomic assays improve patient outcomes beyond merely predicting risks. At PLOS Medicine, initiatives aiming at evaluating both treatment strategies and the viability of de-escalation alongside precision medicine are welcomed, especially when they provide insightful metrics on patient experiences, treatment burdens, and overall quality of life.
Balancing the gains made in breast cancer therapies with the necessity to avoid overtreatment is crucial. Informing patients about the risks and benefits associated with different treatment modalities will empower them to make well-informed choices regarding their health. A deliberate emphasis on de-escalation coupled with active surveillance offers not just a route to enhanced health outcomes but also a commitment to holistic patient care, ultimately benefitting survivors long after initial treatment concludes.